Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR

Emily M. Ploeg(University Medical Center Groningen), Wijnand Helfrich(University Medical Center Groningen)
Journal for ImmunoTherapy of Cancer
September 1, 2023
10.1136/jitc-2023-006837
Cited by 13

Related Papers

Superior Activity of Fusion Protein scFvRit:sFasL over Cotreatment with Rituximab and Fas Agonists
|Cancer Research|2008|46
Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells
|Journal of Molecular Medicine|2008|30
Cationic amphiphilic drugs as potential anticancer therapy for bladder cancer
|Molecular Oncology|2020|15
A Novel Bispecific Antibody for EpCAM-Directed Inhibition of the CD73/Adenosine Immune Checkpoint in Ovarian Cancer
|Cancers|2023|5